Higher Incidence and Rising Prevalence to Drive Breast Cancer Therapeutics Market to USD 12.8 Billion by 2020 - iHealthcareAnalyst, Inc.

Maryland Heights, MO, July 08, 2016 --(PR.com)-- Breast Cancer Therapeutics Market – Global Breast Cancer Drug Classes Analysis and Forecast 2013-2020, estimates the global breast cancer therapeutics market to reach nearly USD 12.8 Billion in 2020, at a CAGR of 8.5% from 2016 to 2020 - iHealthcareAnalyst, Inc.

Visit the Breast Cancer Therapeutics Market – Global Breast Cancer Drug Classes Analysis and Forecast 2013-2020 report at http://www.ihealthcareanalyst.com/report/breast-cancer-therapeutics-market/

Breast cancer therapeutics include hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules. The global breast cancer therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes – brand name (chemical name) such as antimetabolites – Gemzar (gemcitabine), aromatase inhibitors - Afinitor (everolimus), Arimidex (anastrozole), Aromasin (exemestane), Femara (leterozole), Ibrance (palbociclib); Her2 Inhibitors - Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab), Tykerb (lapatinib); Hormone receptors - Fareston, Faslodex, Zoladex; and Mitotic inhibitors - Halaven (eribulin), Ixempra (ixabepilone), Taxotere (docetaxel), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

The global breast cancer therapeutics market is segmented as:
1. Drug Class
1.1. Antimetabolites
1.1.1.Gemzar (Gemcitabine)
1.2. Aromatase Inhibitors
1.2.1. Afinitor (Everolimus)
1.2.2. Arimidex (Anastrozole)
1.2.3. Aromasin (Exemestane)
1.2.4. Femara (Leterozole)
1.2.5. Ibrance (Palbociclib)
1.3. HER2 Inhibitors
1.3.1. Herceptin (Trastuzumab)
1.3.2. Kadcyla (Ado-Trastuzumab Emtansine)
1.3.3. Perjeta (Pertuzumab)
1.3.4. Tykerb (Lapatinib)
1.4. Hormone Receptor
1.4.1. Fareston
1.4.2. Faslodex
1.4.3. Zoladex
1.5. Mitotic Inhibitors
1.5.1. Halaven (Eribulin)
1.5.2. Ixempra (Ixabepilone)
1.5.3. Taxotere (Docetaxel)

2. Geography (Region, Country)
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. AstraZeneca plc
3.2. Eisai Co., Ltd.
3.3. Eli Lilly and Company
3.4. F. Hoffmann-La Roche Ltd.
3.5. GlaxoSmithKline plc
3.6. Novartis International AG
3.7. Pfizer, Inc.
3.8. Puma Biotechnology, Inc.
3.9. Sanofi S.A.
3.10. Teva Pharmaceutical Industries Ltd.

About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareranalyst.com
Website: http://www.ihealthcareanalyst.com